Stephen Michael Kelsey Sells 5,447 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Stephen Michael Kelsey sold 5,447 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $418,438.54. Following the sale, the insider directly owned 278,600 shares in the company, valued at approximately $21,402,052. The trade was a 1.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Stephen Michael Kelsey also recently made the following trade(s):

• On Monday, October 13th, Stephen Michael Kelsey sold 25,000 shares of Revolution Medicines stock. The stock was sold at an average price of $48.54, for a total value of $1,213,500.00.

Revolution Medicines Price Performance

RVMD stock opened at $78.78 on Friday. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $81.49. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The stock has a market cap of $15.23 billion, a price-to-earnings ratio of -15.24 and a beta of 0.96. The business has a fifty day moving average of $66.73 and a two-hundred day moving average of $49.21.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period last year, the firm posted ($0.94) earnings per share. As a group, research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute?304 (daraxonrasib) resectable pancreatic cancer trial — a near?term clinical milestone that validates program progress and can support longer?term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit?taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Hedge Funds Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. S&CO Inc. lifted its holdings in Revolution Medicines by 54.5% during the 2nd quarter. S&CO Inc. now owns 14,171 shares of the company’s stock worth $521,000 after buying an additional 5,000 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Revolution Medicines during the 2nd quarter worth about $3,639,000. Harbor Capital Advisors Inc. lifted its stake in Revolution Medicines by 64.7% during the second quarter. Harbor Capital Advisors Inc. now owns 58,323 shares of the company’s stock worth $2,146,000 after purchasing an additional 22,906 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Revolution Medicines by 7.6% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 71,311 shares of the company’s stock valued at $2,624,000 after purchasing an additional 5,060 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new position in Revolution Medicines in the second quarter valued at approximately $1,678,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of research analyst reports. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Truist Financial started coverage on shares of Revolution Medicines in a report on Friday, September 5th. They issued a “buy” rating and a $99.00 target price for the company. Royal Bank Of Canada began coverage on Revolution Medicines in a research note on Monday, November 3rd. They set an “outperform” rating and a $77.00 price target on the stock. Wedbush raised their price target on Revolution Medicines from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $78.50.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.